Similar articles

• A review of the rationale and clinical utilization of α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders.

  Sallee F, Connor DF, Newcorn JH. Sallee F, et al. J Child Adolesc Psychopharmacol. 2013 Jun;23(5):308-19. doi: 10.1089/cap.2013.0028. J Child Adolesc Psychopharmacol. 2013. PMID: 23782125 Review.
• Another extended-release α2-agonist for ADHD.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2011 Feb 7;53(1357):10-2. Med Lett Drugs Ther. 2011. PMID: 21304444 Review. No abstract available.
• Psychopharmacology for the clinician: management of comorbid Tourette syndrome and attention-deficit/hyperactivity disorder: are psychostimulants an option?

  Pringsheim T. Pringsheim T. J Psychiatry Neurosci. 2012 Nov;37(6):432. doi: 10.1503/jpn.120127. J Psychiatry Neurosci. 2012. PMID: 23092593 Free PMC article. No abstract available.
• Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder.

  Jain R, Segal S, Kollins SH, Khayrallah M. Jain R, et al. J Am Acad Child Adolesc Psychiatry. 2011 Feb;50(2):171-9. doi: 10.1016/j.jaac.2010.11.005. J Am Acad Child Adolesc Psychiatry. 2011. PMID: 21241954 Clinical Trial.
• Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.

  Huang YS, Tsai MH. Huang YS, et al. CNS Drugs. 2011 Jul;25(7):539-54. doi: 10.2165/11589380-000000000-00000. CNS Drugs. 2011. PMID: 21699268 Review.